Graft Versus Host Disease Treatment Market Analysis and Growth Forecast by 2032

Posted by Ganesh Shinde on February 10th, 2023

The global Graft Versus Host Disease (GvHD) Treatment Market is estimated to reach ,655.37 million by 2032, growing at an 8.3% CAGR.

Corticosteroids and combination therapy for graft-versus-host disease in HCT patients are increasing in popularity, strengthening the market for (GvHD) treatment. In 2022, the market is expected to be worth ,547.86 million USD. The market grew at a 7.8% annual rate between 2016 and 2021.

Allogeneic hematopoietic cell transplant patients may benefit from recent advancements in overall survival and acute graft-versus-host disease (GVHD) severity levels, however, there are a number of challenges that must be addressed. In addition, newer medications such as Jakafi and Rezurock have recently been approved for the prevention and treatment of chronic (GVHD) and may provide a greater benefit than older medications.

For treating adults and pediatric patients with GVHD, Orencia (abatacept) was approved by the U.S. Food and Drug Administration in December 2021. In addition to treating autoimmune disorders, Orencia is also used to prevent them. T-cells are a key component of acute (GVHD), and this drug circumvents their attack by specifically binding to and modulating one of the main costimulation signals sent by these cells.

This prevents a full activation of T-cells, which prevents acute (GVHD) from occurring. A number of new approaches are being evaluated by doctors in order to prevent (GVHD) in the future.

Further, approval of Orencia will make stem cell transplants more accessible to a larger number of cancer patients and people with blood disorders, particularly people from diverse ethnic backgrounds. To improve treatment response, future treatments may include immunosuppression and other treatment agents, such as regenerative or tissue-repairing agents to the market.

Competition Analysis

Key players in the global graft versus host disease (GvHD) treatment market include Sanofi, Equillium, Inc., Novartis AG, Neovii Biotech GmbH, Merck & Co., Astellas Pharma Inc.,Soligenix, Inc., Mesoblast Ltd, Pfizer, Takeda Pharmaceutical, Abbott, and others.

Get More Details@ https://www.futuremarketinsights.com/reports/graft-versus-host-disease-gvhd-treatment-market

Key Segments Profiled In The Global Graft Versus Host Disease (Gvhd) Treatment Market

Graft Versus Host Disease (GvHD) Treatment Market by Product:

• Monoclonal antibodies Graft Versus Host Disease (GvHD) Treatment
• mTOR inhibitors Graft Versus Host Disease (GvHD) Treatment
• Tyrosine kinase inhibitors Graft Versus Host Disease (GvHD) Treatment
• Thalidomide Graft Versus Host Disease (GvHD) Treatment
• Etanercept Graft Versus Host Disease (GvHD) Treatment

Graft Versus Host Disease (GvHD) Treatment Market by Disease:

• Acute Graft Versus Host Disease (a(GvHD)
• Chronic Graft Versus Host Disease (c(GvHD)